South Oklahoma City Man Volunteers to Give Back for Blessings Received

National Volunteer Week was celebrated April 7-13

In his retirement, Fred Selensky enjoys his membership in the Oklahoma City Fiat Car Club and has built many friendships with other car enthusiasts over the years. But his weekly volunteer role has also brought new friendships into his life.
“When I retired, I was looking for a way to give back for the blessings I’ve received,” Selensky said.
So, he signed up to be a volunteer driver for the Retired and Senior Volunteer Program of Central Oklahoma (RSVP) Provide-A-Ride program, which provides low-income seniors transportation to doctor’s appointments. Last year, 66 RSVP Provide-A-Ride volunteers drove more than 400 clients to 6,065 medical appointments.
“It’s fulfilling a need in the clients I take because they don’t drive and don’t have to pay for a taxi to medical appointments,” he said. “It’s really fulfilling for me, too, and I enjoy doing something people appreciate. It’s not a chore”
April is National Volunteer Month, a month dedicated to honoring volunteers and encouraging volunteerism. Selensky is one of more than 900,000 Oklahomans who gave of their time last year, according to the Corporation for National and Community Service. Research shows that adults who volunteer are more likely to experience health benefits—longer life span and better mental health.
If you are interested in volunteering with RSVP as a Provide-A-Ride driver or with one of the many RSVP nonprofit partners, call 405.605-3110 or visit www.rsvpokc.org.

The National Heart, Lung and Blood Institute has awarded an Oklahoma Medical Research Foundation scientist $5.9 million to study new ways to control bleeding like that which occurs in aneurysms.
OMRF researcher Courtney Griffin, Ph.D., received a seven-year grant to pursue novel research into blood vessel function and factors that lead to uncontrolled bleeding.
“Seven years is like paradise to a scientist. It allows us to address questions and take our research in new directions we couldn’t have before,” said Griffin, who joined OMRF from the University of North Carolina at Chapel Hill in 2008. “This will give us the opportunity to dig in on basic science questions that could lead to new drugs and therapies for devastating conditions.”
The grant was awarded under a new federal granting program known as the R35, which was established to promote scientific productivity and innovation by providing sustained support and increased flexibility in research. NHLBI program officer Yunling Gao, Ph.D., said the R35 award is designed to provide long-term support to outstanding investigators like Griffin who are conducting research that breaks new ground or extends ongoing studies that are making significant contributions to the field.
“Dr. Griffin has been supported by the NHLBI’s programs over the past decade, and she has emerged as an expert in the field on protease-mediated regulation of vascular stability,” said Gao. “We look forward to her new breakthroughs and achievements for years to come.”
Griffin’s work is focused on proteases—proteins that chew up other proteins. At OMRF, she studies the role proteases play in a healthy setting and also the damage they can cause in blood vessel development when they go awry. When blood vessel integrity is compromised, they become weaker and can rupture, which can be fatal.
By knowing what vessels are susceptible and under what conditions, they can identify disease links that may be predictable and lead to the development of therapeutic interventions.
“The competition for these grants is fierce, and you must have an incredible track record to be considered for one of them,” said OMRF President Stephen Prescott, M.D. “The NHLBI is betting on Dr. Griffin, and she is an outstanding choice for this award. I have no doubt she will reward them with her incredible work.”
The grant, No. R35 HL144605, is from the NHLBI, a part of the National Institutes of Health.

Arthritis is the leading cause of disability in adults in the U.S., affecting more than 54 million people with more than 100 distinct types of the disease.
To make matters worse, there are no approved treatments for the most common form of arthritis—osteoarthritis. It stems from the loss of cartilage between bones and joints and will affect more than half of all Americans over the age of 65.
Understandably, this has led to much concern about the future of arthritis treatment.
“We all want to live long enough that we eventually have some wear-and-tear form of arthritis,” said Oklahoma Medical Research Foundation Vice President of Clinical Affairs Judith James, M.D., Ph.D. “But we don’t want any disability or limitations from it that tend to occur as we age. What we need is a disease-modifying drug.”
James, a rheumatologist and internationally recognized expert on arthritis, said that advancements in treating other forms of arthritis offer hope for similar developments in osteoarthritis.
“In the past decade, we have seen big changes in treatment for several types of arthritis, including the introduction of drugs and interventions for less-common forms like rheumatoid arthritis,” said James.
Rheumatoid arthritis is a chronic illness mainly characterized by inflammation in the lining of the joints, and it affects more than 1.3 million adults in the U.S. James currently serves as principal investigator on a clinical trial called StopRA, a prevention study for the disease.
“We are testing people who are at high risk of developing RA. Our goal is to get them on treatments that may help prevent the disease from ever occurring,” she said. If you are interested in participating or finding out more about the study, please call 405-271-7745 or email jackie-keyser@omrf.org.
The National Institutes of Health invests more than $500 million annually toward understanding and treating various forms of arthritis. Some of that work is happening at OMRF, including research by scientist Tim Griffin, Ph.D., who studies the effects of obesity on the development of osteoarthritis.
“Much of what we initially learned about osteoarthritis came from studying end-stage diseased tissues when people had their joints replaced,” said Griffin.
However, technological advances in imaging and biomarkers have allowed scientists to study earlier stages of disease. Griffin says that this has given new hope for a cure.
“We now think of early-stage OA as resulting from a family of different conditions, such as obesity, trauma, or aging,” he said. “Treatments that target the specific cause of osteoarthritis at the early stages may delay or even prevent disease.”
Multiple studies have shown that a diet avoiding inflammatory foods like saturated fats and refined carbohydrates can help protect you. Griffin’s lab recently found that diets high in saturated fats increased the risk of joint inflammation in mice—even before cartilage loss began.
“We are working on this disease in earnest and continue to understand more and more about it,” said James. “I am increasingly hopeful that we will see a treatment for osteoarthritis in our lifetime.”
But while we await the first osteoarthritis drug, what can we do in the meantime?
“‘Move as much as you can,” said James. “The more you sit, the stiffer and more painful your joints become. Other keys are to maintain a reasonable body weight and participate in joint-safe exercises like swimming or using an elliptical machine.”